Peptide Briefing

Eli Lilly Has Sued 11 Retatrutide Sellers. Here Is What the Complaints Say About "Research Use Only"

Lilly filed six suits in August and five more on October 8, 2026, against online peptide stores, med spas, a weight-loss clinic and a compounding pharmacy. We read the complaint against LiveWell Peptides: the evidence of human use includes a shopping cart, volume discounts, a 21+ age gate and bacteriostatic water linked from the product page.

By Peptide Briefing · October 20, 2026 · 6 min read

Eli Lilly has now sued 11 U.S. businesses over retatrutide, its triple-agonist obesity drug that is still in clinical trials and has no approval anywhere. Six suits were filed on August 12, 2026, and five more on October 8. The defendants include online "research use only" peptide stores, med spas, a weight-loss clinic and a compounding pharmacy.

Two of the October defendants are in this directory: Cenexa Labs and LiveWell Peptides. Both listings now show the case. We pulled the dockets from the federal courts' public records and read the complaint against LiveWell, which is public; the one against Cenexa is not yet. What follows is what Lilly alleges. No court has ruled on any of it.

Who has been sued

Status is from the public dockets on CourtListener as of October 20, 2026, unless noted.

August 12, 2026

  • Aesthetic Envy Cosmetic Centers (med spa), E.D. Cal. 2:26-cv-02764. Lilly filed a notice of voluntary dismissal on September 11.
  • Astra LLC (online seller), W.D. Tex. 5:26-cv-05147. Lilly amended its complaint on August 31.
  • Legendary Peptides (online seller), E.D. Tex. 1:26-cv-00347. Served August 12; a third-party case tracker reports a motion to dismiss filed October 2.
  • Striker Pharmacy (compounding pharmacy), S.D. Tex. 4:26-cv-06563. Active; the parties filed a joint case-management plan on October 5.
  • Texas Peptides (online seller), W.D. Tex. 5:26-cv-05146. Lilly told The Washington Post it had settled two of the August cases, and a case tracker names Texas Peptides as one. The docket does not show a settlement yet.
  • Lone Star Peptide Co. (online seller), S.D. Tex. 4:26-cv-06562. Active.

October 8, 2026

  • American Peptides LLC (online seller), W.D. La. 5:26-cv-04146. Complaint filed.
  • Cenexa Labs LLC (online seller), S.D. Tex. 4:26-cv-08806. Complaint filed. Docket.
  • William "Ian" Brown, d/b/a LiveWell Peptides (online seller, Dallas), N.D. Tex. 3:26-cv-03514. Complaint filed. Docket.
  • Southlake Mhya PLLC, d/b/a Medrein Health & Aesthetics (med spa), N.D. Tex. 4:26-cv-01294. Complaint filed.
  • MedShape Weight Loss Clinic (clinic, Arizona), D. Ariz. 2:26-cv-07361. Complaint filed.

Lilly also says it has reported more than 200 people and businesses to the FDA, the Department of Justice, state attorneys general and licensing boards, and more than 14,000 websites, ads, social posts and product listings to the platforms that host them.

Why the claims are under state law

Only the federal government can enforce the federal drug law, the FD&C Act. A drug company cannot sue a competitor under it. So Lilly uses state consumer-protection statutes instead. The LiveWell complaint has eight claims: unfair competition under the laws of Alaska, Colorado, Connecticut, North Carolina, South Carolina, Tennessee and Washington, each tied to that state's ban on selling unapproved new drugs, plus unfair competition under Texas common law. Lilly asks for a permanent injunction, the seller's profits, damages and legal fees.

The complaints against the clinics and med spa take a different route, reportedly alleging false advertising over claims about clinical trials, comparisons to approved drugs and regulatory status.

What Lilly says made the "research use only" label meaningless

Lilly's core argument is that a research-use label does not matter when everything else about a store points to people injecting the product. In the LiveWell complaint, the evidence is:

  • Reconstitution built into the sale. The retatrutide page told buyers to "reconstitute with bacteriostatic water" and linked to the store's own bacteriostatic water "for peptide reconstitution." Lilly argues a research lab would have its own reagents and protocols.
  • Influencer affiliate codes. Social media personalities had discount codes, wore the store's merchandise and credited it for their weight loss, and the store publicly praised their "progress."
  • The owner's dosing education. A "community" offering "reconstitution protocols, dosing calculations, safety practices," and posts explaining that peptides are injected under the skin.
  • Borrowing Lilly's trials. The product page cited Lilly's TRIUMPH trials and listed tirzepatide and semaglutide, the ingredients in approved obesity drugs, as "related research."
  • An ordinary consumer checkout. A shopping cart, volume discounts, free shipping over $200 and an age gate asking buyers to confirm they are 21 or older.

That last point should get the attention of anyone running a research-peptide store, because nearly all of them have every one of those features. On its own, a checkout page is not illegal. Lilly's argument is that taken together, "the entirety" of the store shows who the customer really is. This is the same reasoning the FDA uses in its warning letters, which we covered in our analysis of peptide warning letters: the agency judges intended use from the whole website, not the disclaimer. The complaint itself cites the FDA's March 2026 warning letters to Gram Peptides, Prime Sciences and Pink Pony Peptides over retatrutide.

What is in the products

Lilly has said that suspect retatrutide products can carry too much or too little active ingredient, the wrong ingredient entirely, or contaminants. Pharmaphorum reported that analysis of seized samples found doses ranging from zero to overdose levels and, in some cases, a different active ingredient such as insulin, but the report did not say who ran the analysis. The LiveWell complaint does not describe any testing of LiveWell's own product.

CBS News reported that the FDA has received two reports of deaths involving products sold as retatrutide. Reports to the FDA's adverse-event system do not establish that a product caused a death, and the FDA declined to say whether it had verified either one. Figures circulating online for poison-center calls about retatrutide could not be traced to published data, so we have left them out.

What this means for B2B buyers

  • Buyers are defendants too. Four of the 11 suits target businesses that dispense or administer peptides to patients: two med spas, a weight-loss clinic and a compounding pharmacy. Buying from a research supplier does not move the risk upstream.
  • Supply can vanish overnight. LiveWell's website was offline six days after the suit was filed, and the domain no longer resolves. If you depend on a store that sells retatrutide to consumers, plan for it to disappear.
  • Check the docket, not just the warning-letter database. Lilly's suits do not show up in FDA records. Search the supplier's legal name on CourtListener before you place a large order.
  • Expect more. Two waves in two months, with thousands of listings already reported, suggests Lilly will keep going until it files for approval, which it plans for early 2027.

How listings in this directory show lawsuits

When a listed supplier is named in a lawsuit over selling unapproved drugs, the listing shows a dated notice with the court, the case number and a link to the public docket, and the confidence score is capped at 60 while the case is open. This is the same treatment as an open FDA warning letter. The full rules are on how we score suppliers. If a case is dismissed or settled, the notice is updated to say so.

References